

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported)
March 30, 2021**

Allakos Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-38582
(Commission
File Number)

45-4798831
(IRS Employer
Identification No.)

**975 Island Drive, Suite 201
Redwood City, California 94065**
(Address of principal executive offices, including zip code)

(650) 597-5002
(Registrant's telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol(s)	Name of Each Exchange on Which Registered
Common Stock, par value \$0.001	ALLK	The Nasdaq Global Select Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01 Other Events

On March 30, 2021, Allakos Inc. (the “Company”) issued a press release announcing upcoming presentations related to Eosinophil and Mast Cell-Driven Diseases at the 2021 DDW Annual Meeting. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Description
99.1	Press Release dated March 30, 2021.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Allakos Inc.

Date: March 30, 2021

By: _____
/s/ Robert Alexander
Robert Alexander
Chief Executive Officer

Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2021 DDW Annual Meeting

REDWOOD CITY, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced the acceptance of two oral and five poster presentations at the upcoming Digestive Disease Week (DDW) Annual Meeting.

The presentations will take place during the DDW Annual Meeting being held virtually from May 21 to 23, 2021, at which time ePosters and ePapers will be available from the DDW ePosters and ePapers website. Abstracts will be available on the ePosters and ePapers website in April, and in the May online supplement to Gastroenterology.

Prevalence Data Presentations:

Presentation (Presenter): Endoscopy and Systematic Biopsy of Patients with Chronic Gastrointestinal Symptoms Leads to High Discovery Rate of Patients Who Meet Histologic Criteria for Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Nicholas Talley MD PhD)

Session (Time): Novel Insights into the Pathogenesis and Management of Eosinophilic Esophagitis and Gastroenteritis (Presentation #537, May 22, 4:00–4:14pm ET)

Poster (Presenter): Gastroduodenal Eosinophilia is Under-Appreciated in Eosinophilic Esophagitis (EoE) Patients with Functional Bowel Symptoms: A Real Life Experience (Kathryn Peterson MD)

Session (Time): Eosinophilic Esophagitis and Gastroenteritis: Clinical (Session #5105, May 21, 12:15–1:00pm ET)

Long-Term Treatment Presentation:

Presentation (Presenter): Long-Term Treatment of Patients with Eosinophilic Gastritis and/or Eosinophilic with Lirentelimab, a Monoclonal Antibody Against Siglec-8 (Kathryn Peterson MD)

Session (Time): Novel Insights into the Pathogenesis and Management of Eosinophilic Esophagitis and Gastroenteritis (Presentation #539, May 22, 4:28–4:42pm ET)

Mechanism of Disease Presentation:

Poster (Presenter): Activated Mast Cells and Eosinophils are Associated with Increased Inflammatory Mediators in Mucosal Biopsies from Patients with Chronic Gastrointestinal Symptoms (Bradford Youngblood PhD)

Session (Time): Eosinophilic Esophagitis and Gastroenteritis: Clinical (Poster of Distinction, Session #5105, May 21, 12:15–1:00pm ET)

Diagnosis of EG and/or EoD Presentations:

- Poster (Presenter): Optimization of Eosinophilic Gastritis/Duodenitis Detection Requires Evaluation of Multiple High-Powered Fields in Each of 8 Gastric and 4 Duodenal Biopsies: Analysis from a Randomized Trial (Evan Dellon MD MPH)
- Session (Time): Eosinophilic Esophagitis and Gastroenteritis: Clinical
(Session #5105, May 21, 12:15–1:00pm ET)
- Poster (Presenter): Eosinophilic Gastritis and Eosinophilic Duodenitis Exhibit a Similar Clinical Presentation, Underscoring the Need for Collection of Multiple Biopsies from Both the Stomach and Duodenum to Evaluate for Tissue Eosinophilia: Analysis from a Randomized Trial (Nirmala Gonsalves MD)
- Session (Time): Eosinophilic Esophagitis and Gastroenteritis: Clinical
(Session #5105, May 21, 12:15–1:00pm ET)
- Poster (Presenter): Endoscopic Appearance Does Not Predict the Presence of Histologic Eosinophilic Gastritis Among Symptomatic Adults, Indicating that Collection and Evaluation of Biopsies Should Occur Regardless of Endoscopic Appearance: Analysis from a Randomized Trial (Ikuo Hirano MD)
- Session (Time): Eosinophilic Esophagitis and Gastroenteritis: Clinical
(Session #5105, May 21, 12:15–1:00pm ET)

Following the presentations, the posters and slides will be available on the Allakos website.

About Allakos

Allakos is a clinical stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases. The Company's lead antibody, lirentelimab (AK002), is being evaluated in a Phase 3 study in eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD) and a Phase 2/3 study in eosinophilic esophagitis (EoE). Lirentelimab targets Siglec-8, an inhibitory receptor selectively expressed on human mast cells and eosinophils. Inappropriately activated eosinophils and mast cells have been identified as key drivers in a number of severe diseases affecting the gastrointestinal tract, eyes, skin, lungs and other organs. Lirentelimab has been tested in multiple clinical studies. In these studies, lirentelimab eliminated blood and tissue eosinophils, inhibited mast cells and improved disease symptoms in patients with EG and/or EoD, EoE, mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria and indolent systemic mastocytosis. For more information, please visit the Company's website at www.allakos.com.

###

Source: Allakos Inc.

Investor Contact:

Adam Tomasi, President, COO & CFO
ir@allakos.com

Media Contact:

Denise Powell
denise@redhousecomms.com